The pharmaceutical community is excited with anticipation surrounding retatrutide, a new dual GIP and GLP-1 receptor that’s exhibiting significant promise in clinical trials for treating obesity. Unlike some current weight loss treatments, retatrutide appears to offer a more substantial loss in body mass and benefit metabolic markers, particularl